Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25158576 | 1.00 | CYP2A6 (0.41) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL30348140 | 0.89 | CYP2A6 (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL30348302 | 0.89 | CYP2A6 (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL25158234 | 0.89 | CYP2A6 (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL25158579 | 0.89 | CYP2A6 (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL25158074 | 0.88 | CYP2A6 (0.43) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL30348808 | 0.88 | CYP2A6 (0.43) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL25158014 | 0.87 | DYRK1A (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL25197382 | 0.87 | DYRK1A (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 | |
| SCHEMBL30406931 | 0.87 | DYRK1A (0.39) | CYP2A6DYRK1ACLK1TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | claimed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | claimed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | CYP2A6 2959/4885DYRK1A 1/4885CLK1 355/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | CYP2A6 2959/4885DYRK1A 1/4885CLK1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.